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Abstract: The pivotal role of cancer stem cells (CSCs) in the initiation and progression of malignancies
has been rigorously validated, and the specific methods for identifying and isolating the CSCs from
the parental cancer population have also been rapidly developed in recent years. This review aims
to provide an overview of recent research progress of Chinese medicines (CMs) and their active
compounds in inhibiting tumor progression by targeting CSCs. A great deal of CMs and their
active compounds, such as Antrodia camphorate, berberine, resveratrol, and curcumin have been
shown to regress CSCs, in terms of reversing drug resistance, inducing cell death and inhibiting cell
proliferation as well as metastasis. Furthermore, one of the active compounds in coptis, berbamine
may inhibit tumor progression by modulating microRNAs to regulate CSCs. The underlying
molecular mechanisms and related signaling pathways involved in these processes were also
discussed and concluded in this paper. Overall, the use of CMs and their active compounds may be
a promising therapeutic strategy to eradicate cancer by targeting CSCs. However, further studies
are needed to clarify the potential of clinical application of CMs and their active compounds as
complementary and alternative therapy in this field.
Keywords: cancer stem cells; Chinese medicines; molecular targets
1. Introduction
Tremendous progress in cancer treatment has been achieved over the recent decades due to
our growing understanding on the biology of cancer and the development of new technologies
such as the medical imaging, nanotechnology and health information technology [1,2]. However,
overall, for the majority types of cancer, especially the advanced and recurrent-metastatic cancers, the
effectiveness of treatment is still limited [3–5]. The currently available conventional treatment options
for cancer include surgery, cytotoxic chemotherapy, radiation therapy, targeted biological therapy,
immunotherapy or combinations of all these. However, due to the poor prognosis of advanced cancer,
the main goals of the present therapies are still palliative rather than curative. In the last decades of the
20th century, researchers started to focus on the role of a specific subset of cancer cells which display a
high level of treatment resistance, metastasis, and tumor recurrence: the cancer stem cells (CSCs). CSCs
are small populations of cancer cells, which have common properties similar to normal stem cells, such
as the ability of self-renewal and differentiation, resistance to apoptosis, long lifespan and angiogenic
properties. According to cancer stem cell theory, if the conventional therapy can not eliminate CSCs,
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tumor relapse will occur after therapy in most cases. Therefore, development of therapeutic strategies
that specifically target on CSCs is critical in reducing the risk of cancer relapse.
In recent years, many studies have focused on the CSCs related signaling pathway in regulating
cell proliferation and apoptosis. Several molecular signaling pathways such as Hedgehog, Notch
and Wnt are involved in multiple biological processes of CSCs, including tumorigenicity, tumor
development, cell proliferation, survival and differentiation [6,7]. The mechanisms that contribute
to therapeutic resistance of CSCs have also been widely explored in recent years. So far, several
mechanisms have been revealed to generate treatment resistance of CSCs, such as cell cycle
quiescence, enhancing ability of DNA damage repair, acquiring specific cellular morphology as well as
overexpression of anti-apoptotic proteins, drug efflux transporters and detoxifying enzymes [8–10].
Beside the above-mentioned intrinsic or acquired drug resistance properties of CSCs, the acidic
microenvironment around hypoxic cells may provide another protective barrier against anticancer
therapy for CSCs. In addition, the specific microenvironment can also promote cancer invasion and
metastasis by activation of a subset of proteases [11,12]. Epithelial-mesenchymal transition (EMT)
process also improves cancer invasiveness and metastasis by losing polarity and intercellular adhesion
in epithelial cells and forming migratory mesenchymal cells. Notably, these properties have also been
ascribed to CSCs during malignant progression [13,14]. Other mechanisms such as the regulation
by microRNAs also play an important role in modulating CSCs through post-transcriptional gene
regulation [15,16].
In recent decades, Chinese Medicines (CMs) have been increasingly used as an adjunctive
treatment option following surgery, radiation therapy, or chemotherapy for cancer patients worldwide.
The earliest records of tumor in China can be tracked back to the Qin Dynasty (221–207 B.C.) and the
“malignant sores” with “swelling but without ulceration” was recorded by Chinese Medicine (CM)
classics at that time. According to the theory of CM, cancer is a systematic disease and the imbalance
in the internal functions of the body causes toxin and heat accumulation, as well as blood stasis which
eventually leads to incapability in resisting external carcinogenic factors [17]. For ages, CMs have been
applied in minimizing disability, protecting cancer patients from cancer complications, reducing side
effects of conventional therapy and improving quality of life. According to the latest research, it is
found that CMs might be effective in inhibiting cancer progression by targeting CSCs. Both in vitro
and in vivo studies have confirmed the effect of CMs or their active compound on the hallmarks of
CSCs. Many previous reviews have dealt with the therapeutic effect of CMs on cancer and several
reviews have summarized the present natural products to influence the biology of CSCs. however,
to our knowledge; the effect of CMs on CSCs has not been systematically reviewed [18–20]. In this
paper, we retrieved data from the recent 10-year studies on the anti-CSCs effect of CMs and their
active compounds from databases including Medline, NCBI, CNKI and clinicaltrial.gov. We critically
reviewed the recent update of the anti-CSCs property of CMs and their active compounds, with
emphasis on elaborating the biological effects and the molecular mechanisms of action.
2. Cancer Stem Cells (CSCs) Identification and Isolation
Various analytical methods based on the unique features of CSCs have been used to identify
and isolate CSCs. These methods include sphere-forming assays, side population (SP) analysis, and
fluorescence-activated cell sorting (FACS) or magnetic activated cell sorting (MACS) with antibodies
directed at cell surface markers [21,22]. Sphere-forming assays are in vitro method used to identify
CSCs by their ability of sphere-forming in soft agar or serum-free medium. SP analysis is achieved by
isolating CSCs based on their dye exclusion capacity caused by over-expression of ATP-binding cassette
(ABC) transporters in CSCs. The most widely used method for identification and isolation of CSCs is
MACS or FACS, which target the specific cell markers on CSCs. The cell surface bio-markers used for
identification and isolation of CSCs in various kinds of cancers are summarized in Table 1. As several
cell surface bio-markers which used for isolating CSCs are also expressed in their corresponding adult
stem cells such as CD133 [23], thus, identification of CSC-specific bio-markers are important in future
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research. In addition, none of these methods mentioned above are exclusively used to identify and
isolate the CSCs, a combination of these assays would be more reliable to identify and isolate CSCs.
Although these in vitro methods have been extensively studied for identification and isolation of CSCs,
the gold standard assay for identification and isolation of CSCs is using in vivo xenotransplantation [24].
Normally, the CSCs fractions derived from above mentioned in vitro isolation assay will have much
higher frequency to form tumors in xenograft animals than non-CSCs fractions.
Table 1. The cell surface bio-markers for identification and isolation of cancer stem cells (CSCs) in
different kinds of cancers.
Cancer Type Cell Surface Bio-Markers Reference
Acute myeloid leukemia CD34+ CD38´ [25]
Acute lymphoid leukemia CD34+ CD19´ [26]
Breast cancer CD44+/CD24´/ESA+ [27]
Liver cancer CD133+/CD44+; EEpCAM+; CD90+ [28,29]
Colorectal cancer CD133+/CD44+ [30,31]
Prostate cancer CD44+/CD24´; CD166+; CD151+; p63+ [32]
Lung cancer CD166+; Sca+/CD45´/Pecam´/CD34+ [33]
Head and Neck cancer BMI-1+; CD44high/ALDH1+ [34,35]
Non Hodgkin Lymphoma ABCG2+ [36,37]
Multiple Myeloma CD138+ [38,39]
Bladder cancer CD44+; CD47+; CK5+ [40]
Osteosarcoma CD133+; CD117+ (c-Kit); Stro-1+ [41]
Glioblastoma cancer CD133+; Sox2+; Nestin+ [42,43]
Nasopharyngeal carcinoma CD44+; CD38+ [44,45]
Cholangiocarcinoma CD133+; EpCAM+; CD24+ [46,47]
3. Recent Research Progress on the Biological Function of CSCs in Tumor Progression
3.1. Drug Resistance-Related Properties of CSCs
Several mechanisms have been reported to cause drug resistance in CSCs (Figure 1), such as cell
cycle quiescence, acquiring specific morphological changes, DNA repair ability and overexpression
of drug efflux transporters and detoxifying enzymes. Recent studies have shown that the CSCs are
quiescent in resting stage of cell cycle, which are insensitive to chemotherapy as most chemotherapy
agents mainly target on proliferating cells. Increased expression of DNA repair proteins in
CSCs indicate that abnormal rapid DNA repair also takes part in drug and radiation resistance.
The expression of efflux transporters from the ATP-binding cassette (ABC) gene family in CSCs is
considered to be an important factor for drug penetration and resistance. These pumps also exist in
normal stem cells for effective preservation of their genome from chemical mutagens and prevention
of tumorigenesis [48]. Furthermore, a specific cancer microenvironment (Niche) provides additional
protection against cancer therapy for CSCs. Hypoxia has been considered as a major feature of the
CSCs microenvironment and the major cause for drug resistance and enhanced tumorigenicity of
CSCs. The specific protective microenvironment allows CSCs to hide in a quiescent state in tissues
and evade the attack from chemotherapy. Niche-related drug resistance in CSCs strongly depends on
the adhesion of cancer cells to extracellular matrix via integrins [10,49]. Overexpression of integrin β1
receptors promoted drug resistance in cancer cells. Morozevich et al. found that Doxorubicin-resistant
breast cancer cells significantly overexpressed integrin α5β1 receptors compared with wild-type cancer
cells [50,51].
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3.2. Signaling Pathways Involved in Regulating Proliferation and Cell Death in CSCs
Evasion from apoptotic or autophagic cell death and unlimited proliferation are another major
characteristic of CSCs (Figure 2). Studies showed that CSCs exhibited resistance to TNF-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis; The FLICE-inhibitory protein (FLIP) has been
associated with the resistance of CSCs towards TRAIL. CSCs with high expression of CD133 were
showed to upregulate FLIP and are resistant to TRAIL-induced apoptosis compared with populations
with low CD133 expression [52]. Overexpression of IAP proteins also plays an important role in the
resistance to apoptosis of CSCs. The IAP family of proteins comprises eight human homologues,
which block apoptosis signaling pathways at key nodes [53,54]. ARTS/septin 4 isoform 2 is an
apoptosis-related protein in TGF-β signaling pathway; it is an endogenous antagonist of IAP proteins
that has been implied in the control of CSCs. While this protein was originally named according
to its role in promoting TGF-β-induced apoptosis, it has subsequently been shown to be broadly
implicated in regulating apoptosis signaling via direct binding and antagonizing X-linked inhibitor of
apoptosis protein (XIAP). In addition, the overexpression of IL-8 receptor CXCR1 in CSCs protected it
from apoptosis [55]. Autophagic cell death also plays an important role in regulating chemoradiation
resistance, self-renewal and differentiation in CSCs. Bcl-2/Bcl-XL signaling pathway is related to
the regulation of autophagic cell death in CSCs. In addition, several other autophagic proteins such
as AMPK, Atg5 and Atg12 are also involved in this process [56,57]. CSCs have shown extensive
proliferative potential in various in vitro and in vivo assays. The related molecular mechanisms
have also been widely studied in recent studies. It has been confirmed that the Wnt-β-catenin
signaling pathway plays a pivotal role in CSCs proliferation [58,59]. The combination of Wnt and its
transmembrane receptors frizzled (Frz) can activate the Dishevelled (Dsh) and lead to the inactivation
of glycogen synthase kinase 3 beta (GSK3β), which result in the accumulation of β-catenin and the
transcription of down-stream proliferation related genes. Several inflammatory cytokines such as IL-6,
IL-1β, and IL-8 also play an important role in promoting CSCs self-renewal and proliferation [60].
The activation of STAT3 by IL-6 has been proved to promote CSCs growth and proliferation [61].
IL-6 also activates the recruitment of mesenchymal stem cells, which produce CXCL7 to induce the
proliferation of CSCs in the tumor [62]. In addition, the PI3K/AKT/mTOR pathway also plays a
pivotal role in promoting CSCs proliferation [63,64].
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3.3. Inducing Differentiation in CSCs
Besides destructing cancer cells, another way to restrict cancer progression is to induce the
differentiation of cancer cells. Differentiation therapy aims at inducing the re-activation of endogenous
differentiation programs and resuming the process of maturation of cancer cells. CSCs have the ability
to self-renew, which similar t normal stem cells. Diff rentiation therapy can cause CSCs to differentiate
an lose the ability of s lf-renewal. Th efficacy of retinoic acid-induced differentiation has b en
demonstrated in glioma ce tly [65]. Som CSCs prefer to keep in the cy ling state and are prevented
from differentiation due to the aberrant chromatin modificatio . In that cas , agents that target on
regulating aberra t chromatin modifying enzymes may in uce effective differentiation of CSCs [66].
For example, histone deacetylase can catalyze the acetyl groups to separate from the N-terminal
lysine residues of core nucleosomal histones. Modification of the acetylation status in core histones
can regulate the transcription of several differentiation-related genes. The dysfunction of histone
deacetylase activity has been associated with the development of cancers [67]. The histone deacetylase
inhibitor, suberoylanilide hydroxamic acid, have been recognized as a differentiation inducer in
murine erythroleukaemia cells and applied in preclinical studies for inducing CSCs differentiation [68].
The bone morphogenetic proteins (BMPs) can also induce differentiation in CSCs. Previous study found
that BMPs reduced the number of CSCs in glioma cells and transformed CSCs into non-malignant
cells [69].
3.4. CSCs in Tumor Metastasis
Metastasis refers to the condition that cancer cells change their microenvironment, move to the
circulation, and grow in distant organs, which finally causes multiple organs failure. Recent studies
have found that EMT may generate cells having stem cell phenotypes similar to CSCs [70,71]. These
studies revealed that CSCs might promote metastasis through acquiring the mesenchymal property.
When cancer cells interact with macrophages, fibroblasts, granulocytes, and other cells in niches, these
cells may release some signaling molecules to induce EMT and further improve metastasis [13,72].
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Cancer-related lymphangiogenesis and angiogenesis also play important roles in promoting tumor
metastasis. CSCs may take part in lymphangiogenesis and angiogenesis through producing various
angiogenic and lymphangiogenic factors [73]. A recent study has compared differentially expressing
genes in breast cancer cell lines with high or low lymphatic metastatic ability. The results revealed
that breast cancer cell lines with high lymphatic metastatic ability have a higher proportion of cells
with CSCs properties (CD44+/CD24´) and a greater ability to grow in foreign microenvironment [74].
Wakamatsu et al. detected the expression of CSCs markers such as CD44, ALDH1 and CD133 from
the primary gastric cancer and the lymph node metastasis. The results showed that cancer cells from
lymph node metastasis have a higher proportion of CSCs phenotype than in the primary gastric
cancer [75]. These findings indicate that CSCs may promote the process of cancer metastasis and it can
be a potential anti-metastasis target for a future study.
3.5. The Role of MicroRNAs in the Regulation of CSCs
MicroRNAs (miRNAs) are small noncoding RNAs containing about 21–25 nucleotides. They can
silence their cognate target genes by mRNA degradation or translation suppression by binding to the
31-untranslated region of mRNA. Recently, several miRNAs have been confirmed with the ability of
regulating CSCs. The differential expression profiles of miRNAs in normal cells and CSCs demonstrate
the important role of miRNAs in oncogenesis. The regulatory functions of miRNAs in CSCs may
become potential therapeutic targets for inhibiting tumorigenesis and tumor development. Previous
studies have shown that miRNAs have both suppressive and activation roles in regulating of CSCs.
He et al. showed that up-regulating the expression of miR-200c inhibited breast CSCs-mediated colony
formation and suppressed tumorigenesis in mice [76]. Johnson et al. found that let-7 miRNAs could
suppress oncogenes like RAS and HMGA2 and inhibited CSCs growth [77]. In contrast, miR-19 and
miR-155 have been proved as oncogenic miRNAs, which could significantly facilitate the self-renewal,
colony formation of CSCs and tumor progression [78,79]. In addition, miRNAs can act as a crucial
epigenetic modifier for regulating CSCs. Song et al. showed that miR-22 may act as a pivotal
epigenetic regulator and EMT promoter through miR-200 silencing by direct targeting on the ten
eleven translocation family of methylcytosine dioxygenases in breast CSCs [80].
4. Chinese Medicines (CMs) and Their Active Compounds as Potential Therapeutics
against CSCs
4.1. CMs and Their Active Compounds for Reversion of Drug Resistance of CSCs
Berberine is a plant alkaloid extracted from the rhizomes of Coptis chinensis Franch, one
of the 50 fundamental herbs used in Chinese Medicine. In recent years, berberine has been
intensively studied by our research group and other researchers for its remarkable anti-cancer
and anti-inflammatory activities [81–86]. A recent study has reported that berberine decreased the
proportion of side-population (SP) cells in breast cancer and reversed drug resistance by inhibiting
ABCG2 protein expression [87]. To further explore whether berberine can reverse drug resistance by
targeting breast CSCs, another study found that the modified berberine liposomes could penetrate
cellular membrane and accumulated in the mitochondria of breast CSCs, which in turn suppressed the
activity of ABCC1, ABCC2, and ABCC3 [88]. The in vivo studies from the same group were performed
on human breast CSCs xenografts in nude mice; the result also indicated the anti-cancer effects of
berberine by targeting CSCs.
Oxymatrine is one of the quinolizidine alkaloid compounds extracted from the root of the
traditional Chinese herb, Sophora flavescens Aiton. Previous studies have shown that oxymatrine
possesses activities of anti-apoptosis, anti-fibrotic tissue development, anti-inflammation and
anti-cancer [89–91]. In recent studies, oxymatrine has been found to reduce the proportion of SP
cells in breast cancer MCF-7 cell lines by 90%. SP cells reflected a population with capacity of
drug resistance and self-renewal, which corresponded to characteristics of the cancer stem cells.
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Results showed that compared with the conventional chemotherapy (cisplatin), oxymatrine exhibited a
stronger inhibitory effect on SP cells and a lower inhibitory effect on non-SP cells. This result indicated
that the MCF-7 CSCs (SP cells) were more resistant to conventional chemotherapy than non-cancer
stem like cells. In contrast, oxymatrine can inhibit these drug resistant CSCs (SP cells) and have a
lower toxicity on normal cells. However, the mechanism of reversing drug resistance on CSCs by
oxymatrine still needs further study. Meanwhile, to provide evidences of the resistance reversion effect
by oxymatrine, the synergistic effects of oxymatrine combined with chemotherapy drugs should be
further investigated [92].
Radix Scutellariae, the root of Scutellaria baicalensis Georgi has been used for purging fire and
detoxification in CM. In recent study, the effect of crude Radix Scutellariae extract has been evaluated
in human multiple myeloma cells. The results indicated that though the crude Radix Scutellariae
extract did not show significant anti-proliferative effect in multiple myeloma cells, it could reduce the
proportion of stem-like cells and decrease the expression level of ABCG2 protein in multiple myeloma
cells in vitro [93]. ABCG2 protein is an ATP-binding cassette (ABC) efflux transporter, which was
initially cloned from a multidrug-resistant breast cancer cell line and found to confer resistance to
chemotherapeutic agents such as mitoxantrone and topotecan [94]. Baicalein, a flavonoid isolated
from Radix Scutellariae, also showed inhibitory effect on human myeloma CSCs. The proportion of
SP cells decreased in a dose-dependent manner and the expression of ABCG2 in myeloma cells was
significantly repressed by baicalein treatment. Furthermore, it was shown that both baicalein and
fumitremorgin C (an ABCG2 inhibitor) shared the same binding sites in transmembrane domain. Thus,
baicalein can be a potential anticancer agent to reduce drug resistance induced by CSCs [95].
Bufalin is one of the effective components isolated from Venenum Bufonis. It constitutes the major
digoxin-like immunoreactive component of Venenum Bufonis obtained from the parotid venom and
skin glands of toads. In CM, Venenum Bufonis has been used for inducing resuscitation, refreshing
mind, relieving toxicity and alleviating pain. Bufalin is a cardioactive C-24 steroid that exhibited a
variety of biological activities, such as cardiotonic, anesthetic and blood pressure stimulatory effects.
Recently, many studies have shown the anti-tumor effects of bufalin, including inhibiting tumor cell
proliferation and inducing apoptosis in various cancers [96–98]. A latest inspiring discovery showed
new anti-tumor mechanism of bufalin through modulating drug resistance in CSCs. In this study,
the chemo-resistant subpopulation of osteosarcoma cell lines, which were cultured in CSCs-specific
medium, was treated with bufalin in vitro. After the treatment, those chemo-resistant stem-like cells
lost their ability of differentiation. Moreover, treatment with bufalin also suppressed the proliferation
of these stem-like cells [96]. It provided a promising natural agent for reversing drug-resistance in
cancer treatment. However, the mechanisms underlying reversal from chemo-resistance and its safety
dosage as well as the in vivo efficacy still need to be further investigated.
Tien-Hsien Liquid (THL), a CM herbal formula, which mainly consists of extracts from 14 herbs,
has been used as a complementary anticancer agent and dietary supplement to help strengthen the
body’s immune system for more than 20 years worldwide [99–102]. It has been shown to inhibit
metastasis, angiogenesis and tumor growth in animal model [103]. A study by Yao et al. investigated
the effect of THL on the CSCs isolated from Huh7 hepatoma cells. After treating with THL, the viability
and colony formation of isolated Huh7 stem-like cells were effectively suppressed, and the expression
of stem-ness genes was reduced. The tumorigenicity of these treated cells was also diminished in
NOD/SCID mice. The most attractive discovery in this study is the chemo-sensitization effect by THL
on CSCs. The results showed that when THL or chemotherapy was used alone, the viability of CSCs
decreased by 36% and 5% respectively. However, combination of THL with chemotherapy resulted in
a 63.6% decrease to the viability of CSCs, which indicated a synergistic effect of chemotherapy with
THL. According to the results of mRNA expression, the multidrug-resistant efflux pump gene ABCG2,
which was responsible for drug resistance, significantly decreased after THL treatment. On the other
hand, CD133 was also decreased significantly after THL treatment [104]. CD133 has been shown to
induce chemo-resistance by activating the AKT/PKB and Bcl-2 cell survival response in hepatoma
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cells. Suppression of CD133 could sensitize the hepatic CSCs to chemotherapy [105]. According to a
randomized and controlled phase IIa clinical trial in Taiwan, the Tien-Hsien Liquid Practical (THL-P)
was safe and effective in patients with refractory metastatic breast cancer [99]. Although this research
provided the first supportive evidence for the safety and efficacy of using THL-P in cancer patients, the
limited sample size decreased the data reliability in this study. Further studies for evaluating the safety
and efficacy of using THL-P in combination with conventional therapies and exploring its underlying
anti-cancer mechanisms are needed.
Pien Tze Huang (PZH) is a well-known CM formula that has been used as alternative remedy for
various diseases including cancer for more than 450 years in China and Southeast Asia. The ingredients
of PZH still remain undisclosed by the manufacturer. To our knowledge, its main ingredients are musk,
calculus bovis (gallstone of the ox), snake’s gall, and Radix Notoginseng (root of Panax Notoginseng,
Tien chi/Tianqi/Sanqi in Chinese). Previous studies have shown the anti-tumor effect of PZH by
suppressing STAT3 activation and regulating the Bcl-2 family in colon cancer [106,107]. To further
explore the mechanisms of anti-tumor effect by PZH, study by Shen investigated the effect of PZH
on colon CSCs. The results indicated that PZH could dose dependently decreased the percentage
of colon stem-like cells as well as the viability of these cells. Moreover, PZH exhibited the ability of
reversing drug resistance in CSCs, which was confirmed by the mRNA expression of ABC transporter
superfamily. After the PZH treatment, the expression of ABCB1 and ABCG2 significantly decreased,
thus, it could be a promising drug resistant modulator in complementary treatment for cancer
patients [108].
4.2. CMs and Their Active Compounds for Inducing Cell Death and Inhibiting Cell Proliferation by
Targeting CSCs
The rhizome of Polygonum cuspidatum Siebold & Zucc. (Hu Zhang) is commonly used for
promoting blood circulation and relieving pain, clearing heat and detoxifying in CM. Resveratrol, a
type of natural phenol and phytoalexin, is famous antioxidant supplement for antiaging and cancer
prevention. Most resveratrol products in the USA market contain extracts from Hu Zhang [109].
Modern pharmacological researches showed that Hu Zhang and resveratrol have anti-inflammatory
and anti-tumor effect [110,111]. The latest research has shown that resveratrol could inhibit the
expression of pluripotency maintaining factors (Nanog, Sox-2, c-Myc and Oct-4) in pancreatic CSCs
and induce apoptosis by inhibiting Bcl-2 and XIAP expression, and activating capase-3/7 in CSCs.
Furthermore, this study also showed that the expression of ABCG2 decreased significantly in human
pancreatic CSCs after resveratrol treatment. It was found that resveratrol could inhibit the pancreatic
tumor size and weight as well as suppress pancreatic intraepithelial neoplasia (PanIN) lesions in tumor
xenograft mice [112]. These data suggested that resveratrol could be a potential anti-cancer agent by
targeting on pancreatic CSCs.
Turmeric (Rhizome of Curcuma longa L.) is a conventional herb in CM and Indian Ayurvedic
medicine. Curcumin is a diarylheptanoid isolated from turmeric, which has been proved to be
an effective anticancer agent through various mechanisms such as promoting apoptosis, inhibiting
metastasis, scavenging reactive oxidative species (ROS), and reducing the inflammation associated
tumor microenvironment [113–115]. Recent studies have suggested that curcumin could inhibit STAT3
phosphorylation, cell proliferation, tumor sphere formation in colon CSCs. It also down-regulated the
expression of STAT3-target gene such as c-fos, c-jun and induced apoptosis in colon CSCs. Furthermore,
it was found that curcumin could suppress murine colon CSCs growth from both SW480 and HCT-116
cell lines [116]. Another study revealed that combined treatment of curcumin with epigallocatechin
gallate reduced the CSCs population in breast cancer cells via inhibiting STAT3 phosphorylation,
retaining STAT3-NF-κB interaction and inducing apoptosis in CSCs [117].
Pien Tze Huang could also inhibit the proliferation, and induce the apoptosis in CSCs. A recent
study has found that PZH significantly reduced the proportion of SP cells in colorectal cancer cells
in dose dependent manner. Strikingly, PZH significantly and dose dependently suppressed the
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proliferation and induce apoptosis in colorectal cancer stem-like cells. Moreover, it has been shown
that PZH treatment could down-regulate the mRNA and protein expression of Hes1 and Notch1 in the
stem-like cells. Thus, PZH may suppress the proliferation and induce apoptosis in colorectal CSCs by
inhibiting Notch1 pathway [118].
Propolis has been used for tonifying Qi and dispelling pathogenic factor in CM for thousands of
years. Recent studies found that caffeic acid phenethyl ester (CAPE), a component of propolis, could
inhibit growth of breast CSCs. After CAPE treatment, CD44, the surface biomarker of breast CSCs,
decreased by 95% [119]. The results suggested that CAPE could inhibit breast CSC proliferation and
progenitor formation as well as suppress clonal formation on soft agar in dose-dependent manner, yet
apoptosis was not induced by CAPE treatment. Interestingly, in this study, a contradictory finding
showed that the cell cycle progression of breast CSCs was remarkably promoted after CAPE treatment.
This may be attributed to the reduction of quiescent cells, which make breast tumor tissue become
more sensitive to growth inhibition by CAPE. Future studies should further explore the potential
molecular mechanisms of the anti-CSCs effect by CAPE.
Berberine has been shown to induce apoptosis in cancer cells via various pathways such as
activating the mitochondrial apoptotic pathway, regulating the activation of Bcl-2 family members as
well as activating caspases and inducing the cleavage of poly (ADP-ribose) polymerase-1 (PARP-1).
In addition, berberine can change the mitochondrial membrane potential (MMP), which decreases
the expression of Bcl-2 and Bcl-xL [120–123]. A recent study has shown that the modified berberine
liposomes might also induce apoptosis of breast CSCs via activating the Bax protein while inhibiting
the Bcl-2 protein, which finally activate the mitochondrial apoptosis pathway. An in vivo study also
confirmed the remarkable anti-cancer effect of berberine on CSCs xenograft nude mice [88].
4.3. CMs and Their Active Compounds for Inducing CSCs Differentiation
Carrot (Daucus carota L.) is a common vegetable, which has also been used in CM to promote
digestion by reinforcing the spleen. The β-carotene is a well-known antioxidant extracted from the
root of carrot and some other fruits, the in vitro and in vivo anti-cancer effects have been confirmed by
many studies [124–126]. Recent studies have found that β-carotene is a potential chemotherapeutic
agent for treatment of neuroblastoma. This effect may be mediated by regulating the differentiation
and stem-ness of CSCs. In the xenograft mice model, β-carotene treatment could significantly inhibited
tumor stemness by down-regulating CSC markers such as Oct 3/4 and DLK1. It could also induce
CSCs differentiation through up-regulating several differentiation markers, such as peripherin, vimentin
and neurofilament [127].
Combination of curcumin with epigallocatechin gallate (EGCG) could synergize against breast
cancer by inducing CSCs differentiation. Further mechanisms study revealed that curcumin and EGCG
selectively inhibited STAT3 phosphorylation, hence suppressed STAT3 translocation into the nucleus.
Interaction between NF-κB and STAT3 was weakened in the nucleus due to the lack of phosphorylated
STAT3. As a result, the expression levels of STAT3-NF-κB target genes were decreased. The decreased
expression levels of these target genes further down-regulated the expression of CD44. As a result,
the CSCs were differentiated into non-stem cells and the stemness of breast CSCs was reduced by
curcumin and EGCG [117].
A recent study has compared the effect of berberine and the present standard pancreatic
anti-cancer drug, gemcitabine on pancreatic cancer stem cells. After berberine and gemcitabine
treatment, the SP cell proportion of pancreatic cancer cells significantly decreased compared to the
control group. In addition, several stem cell-associated genes such as SOX2, POU5F1, NANOG
were significantly decreased after berberine or gemcitabine treatment. These results showed that
both berberine and gemcitabine could exhibit anti-cancer effects by inducing pancreatic CSCs
differentiation [128]. As some studies found that berberine was associated with fewer side effects than
gemcitabine treatment in animal experiments, berberine may be a potential alternative anti-cancer
agent for human pancreatic cancer treatment [129,130].
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Antrodia cinnamomea Chang & Chou (Antrodia camphorate) is a fungus species, mainly grows in
Taiwan. Antrodia camphorate mycelial, a well-known Chinese Medicine has been used as for relieving
alcohol intoxication and liver disease in Taiwan for more than 200 years [131]. In a recent study,
another anti-cancer active component named YMGKI-1 has been isolated from Antrodia cinnamomea
Mycelia. It was found that YMGKI-1 could induce CSCs differentiation in head and neck squamous cell
carcinoma (HNSCC). Treating HNSCC cells with YMGKI-1 could significantly decrease the expression
of aldehyde dehydrogenase (ALDH), which is one of the characteristics of CSCs of HNSCC. In addition,
in vivo studies also showed the diminished tumorigenic abilities of HNSCC cells by YMGKI-1 treatment.
Additionally, YMGKI-1 also significantly suppressed the cell viability of CSCs in HNSCC but not
normal stem cells [132].
4.4. CMs and Their Active Compounds for Inhibiting Metastasis by Targeting CSCs
Curcumin, as aforementioned, could induce CSCs differentiation in breast cancer. Recent study
has showed that curcumin could also inhibit in vitro breast CSCs migration. It was found that curcumin
could suppress β-catenin nuclear translocation, thus inhibit trans-activation of EMT-promoting genes
such as Slug. As a result, E-cadherin expression was restored, thereby increased E-cadherin/β-catenin
complex formation and cytosolic retention of more β-catenin and blocked EMT process and migration
of CSCs [133].
Quercetin is a common health supplement, which is extracted from many herbs such as
Dysosma veitchii (Hemsl. & E.H.Wilson) L.K.Fu. The whole plant of Dysosma veitchii (Hemsl. & E.H.Wilson)
L.K.Fu has been used in CM for removing blood stasis and promoting the subsidence of swelling.
Recent study has demonstrated the combination of quercetin with epigallocathechin gallate (EGCG)
inhibited EMT process and metastasis of prostate CSCs. Results showed that these phytochemicals have
synergistic action in inhibiting self-renewal of human primary prostate tumors and inducing apoptosis
through activating capase-3/7 while inhibiting the expressions of Bcl-2, survivin and XIAP in CSCs.
Furthermore, they could inhibit epithelial-mesenchymal transition by inhibiting the expression of snail,
nuclear beta-catenin, vimentin and slug. They also further reduced activity of LEF-1/TCF responsive
reporter and thereby suppressed migration and invasion of prostate CSC. Since metastasis is a complex
process, combination of conventional therapy with complementary CMs may be beneficial for prostate
cancer treatment [134].
Xiaotan Sanjie (XTSJ) decoction is an herbal formula for dispelling phlegm to soften abdominal
mass in CM [135]. It showed therapeutic effect on gastric cancer by inhibiting cell proliferation and
suppressing metastasis in vitro and in vivo [136–138]. A recent study has proved that XTSJ decoction
may inhibit CSCs migration and invasion by manipulating Notch-1-regulated proliferation of gastric
CSCs [139]. Since Notch-1 is important in the control of CSCs proliferation; regulation of Notch-1
could suppress CSCs proliferation and down-regulate the secretion of vascular endothelial growth
factor (VEGF), thus decreased micro-vessel density and further inhibited cancer metastasis [140,141].
Resveratrol could also inhibit migration and invasion of CSCs by suppressing the process
of EMT in pancreatic cancer. Previous studies have shown that after resveratrol treatment, the
expression of several transcriptional repressors of E-cadherin such as Zeb-1, Slug and Snail significantly
decreased [112]. As mentioned above, resveratrol could suppress pancreatic CSCs characteristics by
inducing CSCs differentiation, and many in vivo studies also proved the anti-metastasis effect of
resveratrol and its underlying mechanisms as well as potential adverse effect [142–145]. Furthermore,
several ongoing interventional clinical trials indicated that resveratrol may be a potential therapeutic
agent for the management of pancreatic cancer [146].
Previous researches showed that Antrodia camphorate mycelial might reduce the risk of
metastasis in certain types of cancers [147,148]. A recent study found that the mycelial fermentation
broth of Antrodia camphorate (MFB-AC) could suppress the growth and metastasis of hepatoma
cells without inducing hepatic enzyme abnormality. Further studies revealed that the anti-cancer
effect of MFB-AC might be associated with inhibition of CSCs in liver cancer. MFB-AC suppressed
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the cellular viability, migration activity, and tube formation ability of the CSCs in hepatoma. It was
showed that MFB-AC could down-regulate the expressions of extracellular VEGF and intracellular
hypoxia-inducible factor-1 alpha (HIF1-α) in CSCs of hepatic cancer [149].
4.5. Targeting CSCs Related miRNAs by CMs and Their Active Compounds
Berbamine (BBM) is a natural compound derived from the Berberis amurensis plant such as
Berberis soulieana Schneid. In CM, the root of Berberis soulieana Schneid was used for clearing heat
and removing toxin. Modern researches have shown that berbamine exhibited anti-tumor activity to
several cancers [150–152]. Recent studies reported that berbamine could reduce cell viability and induce
apoptosis in glioblastoma cells by targeting CSCs-related miRNAs. Results showed that miR-4284
was over-expressed about 4-fold in the CSCs following BBM treatment. Furthermore, transfection of
synthetic anti-sense oligonucleotide against human miR-4284 partially blocked the anticancer effects
of BBM in the glioblastoma-derived CSCs [153].
The role of curcumin in regulating CSC-related miRNAs has also been investigated. Results
showed that curcumin could increase the expression of let-7, miR-26a, miR-101 and miR-200,
and decrease miR-21. These further induced cell apoptosis, suppressed cell proliferation and
down-regulated the expression of marker proteins in CSC-like sphere cells of pancreatic cancer and
prostate cancer [154–158]. The down-stream target proteins regulated by these CSCs-related miRNAs
were involved in multiple cellular signaling pathways such as NF-κB, Wnt, hedgehog, and Notch-1.
Isoflavones are natural flavonoids, which act as phytoestrogens and antioxidants in mammals.
Isoflavones are produced from the members of Fabaceae family such as soybean, which has been
used for relieving edema and detoxifying for thousand years in CM [159]. Several epidemiological
and clinical studies have proved that isoflavone-rich soybean products may inhibit the progression
of certain cancers [160,161]. Genistein, glycitein, and daidzein are the three major components and
the most studied isoflavones in soybean. Recent studies have showed that genistein treatment could
down-regulate the expressions of let-7b, c, d, e, miR-26a, miR-146a, and miR-200, and up-regulate the
expressions of miR-21 and CSCs cell surface markers such as EpCAM and CD44 as well as formation
of pancreatic spheres, all of which are in direct agreement with its anti-tumor activity against human
pancreatic cancer cells [28,88]. These data suggest that genistein has anti-tumor activity, which is in part
mediated by deregulation of several CSC-related miRNAs during the development and progression
of tumors.
The bark or seed cones of Magnolia officinalis Rehd. et Wils (commonly called houpu magnolia)
have been widely used in CM and Japanese kampo medicine. Honokiol is a lignan isolated from the
houpu magnolia and has been identified as one of the active compounds in this herb. In recent study,
honokiol was proved with the ability of inhibiting metastasis of renal cancer cells by suppressing
EMT and CSCs properties through regulating miR-141/ZEB2 signaling. In addition, honokiol could
suppress renal cancer growth in vivo. Further mechanistic study demonstrated that honokiol could
increase miR-141 expression, which further regulated ZEB2 expression. These results showed that
honokiol may reverse EMT and inhibit CSC properties through the miR-141/ZEB2 axis [162,163].
As a popular beverage, green tea originated in China for more than 4000 years ago, but its
production has spread to many countries since 19th century. As the oldest herbal tea, green tea has
been used for quenching thirst, decreasing internal heat, inhibiting dysentery and dehumidification
in CM [164]. Recent studies found that the mixture of green tea catechins (GTC) can significantly
inhibit CSCs features and miRNA signaling in pancreatic ductal adenocarcinoma. Combination of
sulforaphane or quercetin with GTC has stronger anti-CSCs effects than using the single agent. Further
mechanism studies showed that GTC combination with sulforaphane or quercetin could activate the
expression of miR-let-7a which further inhibited K-ras expression and suppressed CSC features in
pancreatic ductal adenocarcinoma cells [165]. In agreement with data derived from mouse models of
lung and colon cancer, oncogenic K-ras accelerated tumor progression by imposing an immature state
in which the cell differentiation is inhibited.
The tabular summary of action and the related mechanisms of CMs on CSCs were shown as in
Table 2.
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Table 2. The Chinese Medicines and their active compounds as potential therapeutics against cancer stem cells. VEGF: vascular endothelial growth factor; EMT:
epithelial-mesenchymal transition; XIAP: X-linked inhibitor of apoptosis protein; GTC: green tea catechins.
Chinese Medicines
or Their Active
Compounds
The Sources of Medicines or Their
Active Compounds Type of Study Anti-Cancer Target Molecular Mechanism Reference
Berberine Rhizome of Coptis chinensis Franch In vitro and in vivo
Reversed drug resistance in CSCs Inhibited the activity of ABCC1, ABCC2, ABCC3, and ABCG2 in breastcancer cells. [87]
Induced apoptosis in CSCs Activated the Bax protein while inhibited the Bcl-2 protein, activated themitochondrial apoptosis pathway in breast cancer cells. [88]
Induced CSCs differentiation Inhibited several stem cell-associated genes such as SOX2, POU5F1,NANOG in pancreatic CSCs. [128]
Oxymatrine Root of Sophora flavescens Aiton In vitro Reversed drug resistance in CSCs Undefined. [92,166]
Radix Scutellariaei Aqueous extract of the root ofScutellaria baicalensis Georgi In vitro Reversed drug resistance in CSCs
Decreased the expression level of ABCG2 protein in multiple myeloma
cells. [94]
Baicalein Root of Scutellaria baicalensis Georgi In vitro Reversed drug resistance in CSCs Inhibited ABCG2 by binding the sites in transmembrane domain inmultiple myeloma cells. [95]
Bufalin Pvarotid venom and skin glandsof toads In vitro Reversed drug resistance in CSCs Undefined. [96]
Tien-Hsien Liquid Undefined mixture consists ofextracts from 14 Chinese herbs In vitro and in vivo Reversed drug resistance in CSCs Suppression of CD133 and ABCG2 in hepatoma cells. [104]
Pien Tze Huang Undefined mixture
In vitro Reversed drug resistance in CSCs Suppression of ABCG1 and ABCG2 in colon cancer cell. [108]
In vitro and in vivo
Inhibited proliferation, and
inducing apoptosis in CSCs Suppression of the Notch1 pathway in colon cancer cell. [118]
Induced CSCs differentiation Reduced the mRNA and protein expression of Notch1 and Hes1.
Resveratrol Rhizome of Polygonum cuspidatum
Siebold & Zucc. In vitro and in vivo
Induced apoptosis in CSCs Inhibited the expression of Bcl-2 and XIAP and activated capase-3/7 inpancreatic cancer cells. [112]
Inhibited migration and invasion
by targeting CSCs
Suppression of markers of epithelial-mesenchymal transition
(Zeb-1, Slug and Snail) in pancreatic cancer cells.
Caffeic acid
phenethyl ester Propolis In vitro Inhibited proliferation in CSCs Undefined. [119]
β-carotene Root of Daucus carota L. In vitro and in vivo Induced CSCs differentiation Up-regulated differentiation genes peripherin, vimentin and neurofilamentin neuroblastoma cells. [127]
YMGKI-1 Mycelial of Antrodia cinnamomeaChang & Chou In vitro and in vivo Induced CSCs differentiation Decreased the expression of ALDH genes in HNSCC cells. [132]
Antrodia
camphorata
Mycelial of Antrodia cinnamomea
Chang & Chou In vitro and in vivo
Inhibited migration and invasion
by targeting CSCs
Down-regulated the expression of extracellular VEGF and intracellular
HIF1-α in HCC stem-like cells. [149]
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Chinese Medicines
or Their Active
Compounds
The Sources of Medicines or Their
Active Compounds Type of Study Anti-Cancer Target Molecular Mechanism Reference
Curcumin Rhizome of Curcuma longa L. In vitro
Induced CSCs differentiation Inhibited STAT3 phosphorylation, retained STAT3-NFkB interaction and
down-regulated the expression of STAT3-NF-kB target genes in breast
cancer cells.
[117]
Induced apoptosis in CSCs
Inhibited migration and invasion
by targeting CSCs
Suppressed beta-catenin nuclear translocation thus inhibited
trans-activation of EMT-promoting genes such as Slug in breast
cancer cells.
[133]
Inhibited proliferation, and
induced apoptosis by targeting
CSCs related miRNAs
Increased expressions of let-7, miR-26a, miR-101 and miR-200, and
decreased miR-21 in pancreatic cancer and prostate cancer cells. [154–158]
Honokiol Bark or seed cones of Magnoliaofficinalis Rehd. et Wils In vitro
Inhibited migration and invasion
by CSCs related miRNAs
Increased miR-141 expression, which targeting ZEB2 and further
regulated ZEB2 expression in renal cancer cells. [162,163]
Quercetin The whole plant of Dysosma veitchii
(Hemsl. & E.H.Wilson) L.K.Fu In vitro
Inhibited migration and invasion
by targeting CSCs
Inhibited EMT by inhibiting the expression of snail, nuclear beta-catenin,
vimentin and slug, and the activity of LEF-1/TCF responsive reporter in
prostate cancer cells. [134]
Induced apoptosis in CSCs Activated capase-3/7 and inhibited the expressions of Bcl-2, survivinand XIAP.
Xiaotan Sanjie
decoction
Formula composed of Pinellia tetnata
(Thb.) Breit, Arisaema erubescens
(Wall.) Schott, Poria cocos (Schw.)
Wolf, Citrus aurantium L., Citri
reticulatae viride pericarpium,
Scorpio, Scolopendra, Galli gigerii
endothelium corneum,
Fritillariae cirrhosae bulbus, Semen
brassicae, and
Glycyrrhiza uralensis Fisch
In vitro
Inhibited migration and invasion
by targeting CSCs
Inhibited tumor angiogenesis by manipulating Notch-1-regulated
proliferation of gastric CSCs.
[140,141]
Inhibited the proliferation in CSCs
Berbamine The root of Berberis soulieana Schneid In vitro Induced apoptosis by targetingCSCs related miRNAs
Up-regulated the expressions of miR-4284 more than four-fold and an
anti-sense inhibitor of miR-4284 activity could partially block the
anticancer effects of berbamine on glioblastoma cells.
[153]
Genistein The seed of Glycine max (Linn.) Merr In vitro
Inhibited proliferation, and
induced apoptosis by targeting
CSCs related miRNAs
Down-regulated the expressions of let-7b, c, d, e, miR-26a, miR-146a,
and miR-200, and up-regulated the expression of miR-21 in pancreatic
cancer cells.
[28,88]
Green tea catechins The leaf of Camellia sinensis (L.)O. Ktze In vitro and in vivo
Induced CSCs differentiation by
targeting CSCs related miRNAs
GTC combination with sulforaphane or quercetin activated the
expression of miR-let-7a which inhibited K-ras expression and
suppressed CSC features in pancreatic ductal adenocarcinoma cells.
[165]
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5. Conclusions
With the development of CSCs purification and transplantation techniques, the hypotheses of
CSC models have been further verified in many types of cancers. Both clinical and basic research
have provided credible evidences in support of the presence and crucial biological functions of
CSCs [167–169]. Investigation of CSCs provides potential novel targets for improving therapeutic
efficacy of chemotherapy in cancer treatment. However, there are still many critical issues needing
to be addressed in the future such as the improvement of in vivo tumorigenicity experimental model
of CSCs. So far, most of the supportive evidences for CSCs are derived from xenotransplantation
experiments in immunodeficiency mice. However, the cellular microenvironment in mice is quite
different from human, the human-derived CSCs may be easily generate tumors on mice due to the high
adaptability of the human tumor cell growth in foreign (mouse) cellular microenvironment [170,171].
Thus, a modified in vivo tumorigenicity experimental model is urgently required in future study.
In addition, exploring the origin of CSCs and identification of specific CSCs surface biomarkers should
also be carefully investigated. Although the controversies about the existence of CSCs in cancer have
not ceased since the CSCs theory was established, the CSCs theory does provide a novel prospect
in cancer treatment. As we have summarized above, many CMs and their active compounds may
enhance cancer treatment efficacy by aiming at various characteristics of CSCs, such as reversing
drug resistance, regulating cell proliferation or apoptosis of CSCs, inducing CSCs differentiation
and suppressing tumor metastasis via targeting CSCs as well as regulating CSCs related miRNAs.
Therefore, the CMs and their active compounds, which have shown minimal toxicity to normal cells
may be used against cancers by targeting CSCs. However, it is also desirable that with the increase
of the therapeutic evidences of some undefined mixture of CMs, such as Tien-Hsien Liquid and Pien
Tze Huang, the ingredients of the formulas shall be disclosed for better exploitation of the whole
formula or their active compounds. For future studies, it is imperative to gain more pre-clinical and
clinical evaluations on efficacy and safety of CMs and their active compounds by incorporating novel
technologies in evidence-based medicine and pharmacology.
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